Surgivisio, a Grenoble, France-based innovative medtech company that develops 2D/3D imaging technologies integrating surgical navigation, raised €10.7m in Series B financing.
The round was led by BpiFrance via the PSIM (Major Innovation Support Program) fund, and by Sigma Gestion. Stéphane Lavallée, founder, completed the tour alongside historical private investors.
The company intends to use the funds for the commercial deployment of its imaging system with integrated surgical navigation.
Founded by Stéphane Lavallée, Surgivisio develops 2D and 3D imaging solutions with integrated navigation to assist surgeons in performing multiple procedures, particularly on the spine.
Led by Laurence van Beek and David Armand, Surgivisio’s R & D team will focus on the application for spine surgery, before addressing other segments of orthopedics and traumatology. Protected by more than 19 patents, the device is a highend equipment for advanced healthcare facilities, which has been CE marked by the G-MED (0459) and is now marketed in Europe.
The company is working on the industrialization of its production and the development of its network of distributors and partners, as well as approval from the US regulatory agency, the Food and Drug Administration (FDA), to address the US market.